Aliénor Berges

1.2k citations

34 papers · 843 indexed · h-index 14

Impact in

Oncology top 10%
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
Sensory Systems top 10%
- Olfactory and Sensory Function Studies

Papers in ⓘ

Sensory Systems 4
- Olfactory and Sensory Function Studies 4
Statistics and Probability 5
- Statistical Methods in Clinical Trials 5

Co-authors: Duncan Richards (3 shared papers)Louise Cookson (3 shared papers)Marianna Fontana (2 shared papers)James M. Ritter (1 shared paper)Philip N. Hawkins (2 shared papers)Massimo Pinzani (1 shared paper)Thirusha Lane (2 shared papers)Mark B. Pepys (2 shared papers)
Journals: Cancer Research (4 papers)Clinical Pharmacology & Therapeutics (3 papers)Clinical Cancer Research (2 papers)British Journal of Clinical Pharmacology (2 papers)Current Alzheimer Research (2 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Aliénor Berges

32 papers receiving 825 citations

Peers

Countries citing papers authored by Aliénor Berges

Since Specialization

Citations

This map shows the geographic impact of Aliénor Berges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aliénor Berges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aliénor Berges more than expected).

Fields of papers citing papers by Aliénor Berges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aliénor Berges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aliénor Berges. The network helps show where Aliénor Berges may publish in the future.

Co-authors

The 25 scholars most cited alongside Aliénor Berges, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aliénor Berges Line = papers co-authored together Aliénor Berges links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component New England Journal of Medicine ·Duncan Richards, Louise Cookson, Aliénor Berges, Sharon V. Barton, Thirusha Lane, James M. Ritter, Marianna Fontana, James Moon, Massimo Pinzani, Julian D. Gillmore, Philip N. Hawkins, Mark B. Pepys	2015	261
2	A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease Current Alzheimer Research ·Richard Grove, Conn Harrington, Andreas Mahler, I.J.M. Beresford, Paul Maruff, Martin T. Lowy, Andrew Nicholls, Rebecca Boardley, Aliénor Berges, Pradeep J. Nathan, Joseph P. Horrigan	2014	87
3	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study Clinical Cancer Research ·Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay, Anthony El-Khouiery, Jean‐Charles Soria, Juanita Lopez, Aliénor Berges, S.Y. Amy Cheung, Itziar Irurzun‐Arana, Andrew Goldwin, Brunella Felicetti, Gemma N. Jones, Alan Lau, Paul Frewer, Andrew J. Pierce, Glen Clack, Christine Stephens, Simon A. Smith, Emma Dean, Simon J. Hollingsworth	2021	71
4	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Clinical Cancer Research ·Seung Tae Kim, Simon A. Smith, Peter G. Mortimer, Arsène‐Bienvenu Loembé, Heejin Cho, Kyoung‐Mee Kim, Claire Smith, Sophie E. Willis, Itziar Irurzun‐Arana, Aliénor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, Jeeyun Lee	2021	61
5	The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation Current Alzheimer Research ·Pradeep J. Nathan, Rebecca Boardley, Nicola Scott, Aliénor Berges, Paul Maruff, Tharani Sivananthan, Neil Upton, Martin T. Lowy, Peter J. Nestor, Robert Lai	2013	54
6	Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers European Journal of Cancer ·Timothy A. Yap, Matthew Krebs, S. Postel-Vinay, Yung‐Jue Bang, A. El-Khoueiry, Wassim Abida, Kevin J. Harrington, Raghav Sundar, L. Carter, Eduardo Castanon-Alvarez, Seock‐Ah Im, Aliénor Berges, Maryam Khan, C. Stephens, Gayle Ross, Jean‐Charles Soria	2016	42
7	Unexpectedly high affinity of a novel histamineH₃receptor antagonist,GSK239512,in vivoin human brain, determined usingPET British Journal of Pharmacology ·Sharon Ashworth, Aliénor Berges, Eugenii A. Rabiner, Alan A. Wilson, Robert A. Comley, Robert Lai, Rebecca Boardley, Graham E. Searle, Roger N. Gunn, Marc Laruelle, Vincent J. Cunningham	2013	28
8	Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory Journal of Pharmacokinetics and Pharmacodynamics ·Armin Sepp, Aliénor Berges, Andrew Sanderson, Guy Meno‐Tetang	2015	27
9	Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers Cancer Research ·Matthew Krebs, Juanita Lopez, Anthony B. El-Khoueiry, Yung‐Jue Bang, Sophie Postel‐Vinay, Wassim Abida, Louise Carter, Wen Xu, Seock‐Ah Im, Andrew J. Pierce, Paul Frewer, Aliénor Berges, S.Y. Amy Cheung, Christine Stephens, Brunella Felicetti, Emma Dean, Simon J. Hollingsworth	2018	27
10	Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients Clinical Pharmacokinetics ·Diansong Zhou, Jianguo Li, Khanh Bui, Maria Learoyd, Aliénor Berges, Tsveta Milenkova, Nidal Al‐Huniti, Helen Tomkinson, Hongmei Xu	2018	25
11	Anti‐factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old British Journal of Clinical Pharmacology ·Aliénor Berges, Silvy Laporte, Magali Epinat, Paul Zufferey, É. Alamartine, Brigitte Tranchand, Hervé Decousus, Patrick Mismetti, (unknown)	2007	24
12	Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats Journal of Pharmacokinetics and Pharmacodynamics ·Armin Sepp, Guy Meno‐Tetang, Andrew Weber, Andrew Sanderson, Oliver Schön, Aliénor Berges	2019	22
13	Efficacy and Safety Exposure‐Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients Clinical Pharmacology & Therapeutics ·Diansong Zhou, Jianguo Li, Maria Learoyd, Khanh Bui, Aliénor Berges, Tsveta Milenkova, Nidal Al‐Huniti, Helen Tomkinson, Hongmei Xu	2018	16
14	Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson’s Disease Rating Scales Pharmaceutical Research ·Gopichand Gottipati, Aliénor Berges, Shuying Yang, Chao Chen, Mats O. Karlsson, Elodie L. Plan	2019	13
15	QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019 The Journal of Clinical Pharmacology ·Sarit Cohen‐Rabbie, Aliénor Berges, Dinko Rekić, Joanna Parkinson, Corina Dota, Helen Tomkinson	2021	12
16	Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis CPT Pharmacometrics & Systems Pharmacology ·Tarjinder Sahota, Aliénor Berges, Sharon V. Barton, Louise Cookson, Stefano Zamuner, Duncan Richards	2015	9
17	A Phase 2a, Randomized, Crossover Trial of Gabapentin Enacarbil for the Treatment of Postherpetic Neuralgia in Gabapentin Inadequate Responders Pain Medicine ·R. Norman Harden, Roy Freeman, Michelle Rainka, Lixin Zhang, Chris Bell, Aliénor Berges, Chao Chen, Ole Graff, Kathleen Harding, Setrina Hunter, Sarah Kavanagh, Caryl Schwartzbach, Samantha Warren, Carrie McClung	2013	7
18	Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: A randomized, open-label, three-period crossover study in healthy volunteers Clinical Therapeutics ·Aliénor Berges, C. M. Walls, Shelly E. Lener, Susan A. McDonald	2010	6
19	Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis by Pharmacokinetic-Pharmacodynamic Modelling of Immunohistochemistry Data from Patient Muscle Biopsies PLoS ONE ·Aliénor Berges, Jonathan Bullman, Stewart Bates, David Krull, Nicola Williams, Chao Chen	2015	6
20	Non linear mixed effects analysis in PET PK-receptor occupancy studies NeuroImage ·Aliénor Berges, Vincent J. Cunningham, Roger N. Gunn, Stefano Zamuner	2013	5

About Aliénor Berges

Aliénor Berges is a scholar working on Sensory Systems, Statistics and Probability, Oncology, Nephrology and Hematology, having authored 34 papers that have together received 843 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (9 papers), DNA Repair Mechanisms (7 papers), Statistical Methods in Clinical Trials (5 papers), Olfactory and Sensory Function Studies (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (3 papers), Acute Myeloid Leukemia Research (2 papers) and Migraine and Headache Studies (2 papers). The work is most often cited by research in Oncology (311 citations), Sensory Systems (46 citations), Nephrology (58 citations), Molecular Biology (538 citations) and Immunology (151 citations). Aliénor Berges has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Duncan Richards, Louise Cookson, Marianna Fontana, James M. Ritter, Philip N. Hawkins, Massimo Pinzani, Thirusha Lane, Mark B. Pepys, James Moon and Julian D. Gillmore. Their work appears in journals such as Cancer Research, Clinical Pharmacology & Therapeutics, Clinical Cancer Research, British Journal of Clinical Pharmacology and Current Alzheimer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact